TNF and infection: The United States Food and Drug Administration (FDA) has reported that systemic injection of anti-TNFα Abs (Infliximab [4] and Adalimumab [5]) can lead to serious adverse effects (on-target toxicities) such as severe infections [6, 7], reactivation of viral infections (hepatitis or herpes zoster) [8, 9], and elevated risk of malignancy [4, 5, 10].